160 related articles for article (PubMed ID: 19687425)
1. Cutaneous pigmentation after photosensitivity induced by vandetanib therapy.
Kong HH; Fine HA; Stern JB; Turner ML
Arch Dermatol; 2009 Aug; 145(8):923-5. PubMed ID: 19687425
[TBL] [Abstract][Full Text] [Related]
2. Vandetanib photoinduced cutaneous toxicities.
Doan HQ; Hu MI; Goldstein J; Piha-Paul SA; Subbiah V; Patel AB
Cutis; 2019 May; 103(5):E24-E29. PubMed ID: 31233590
[TBL] [Abstract][Full Text] [Related]
3. A rare cutaneous phototoxic rash after vandetanib therapy in a patient with thyroid cancer: A case report.
Yin Y; Qiu XY; Zhang YH; Zhang B
Medicine (Baltimore); 2019 Aug; 98(31):e16392. PubMed ID: 31374006
[TBL] [Abstract][Full Text] [Related]
4. Successful laser treatment of vandetanib-associated cutaneous pigmentation.
Brooks S; Linehan WM; Srinivasan R; Kong HH
Arch Dermatol; 2011 Mar; 147(3):364-5. PubMed ID: 21422355
[No Abstract] [Full Text] [Related]
5. Selective use of vandetanib in the treatment of thyroid cancer.
Fallahi P; Di Bari F; Ferrari SM; Spisni R; Materazzi G; Miccoli P; Benvenga S; Antonelli A
Drug Des Devel Ther; 2015; 9():3459-70. PubMed ID: 26170630
[TBL] [Abstract][Full Text] [Related]
6. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
Lee JS; Hirsh V; Park K; Qin S; Blajman CR; Perng RP; Chen YM; Emerson L; Langmuir P; Manegold C
J Clin Oncol; 2012 Apr; 30(10):1114-21. PubMed ID: 22370318
[TBL] [Abstract][Full Text] [Related]
7. Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.
Rosen AC; Wu S; Damse A; Sherman E; Lacouture ME
J Clin Endocrinol Metab; 2012 Apr; 97(4):1125-33. PubMed ID: 22378813
[TBL] [Abstract][Full Text] [Related]
8. Vandetanib: in medullary thyroid cancer.
Frampton JE
Drugs; 2012 Jul; 72(10):1423-36. PubMed ID: 22715896
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
Zhang L; Li S; Zhang Y; Zhan J; Zou BY; Smith R; Martin PD; Jiang Y; Liao H; Guan Z
Clin Ther; 2011 Mar; 33(3):315-27. PubMed ID: 21600385
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic hotline. A rare vandetanib-induced photo-allergic drug eruption.
Fava P; Quaglino P; Fierro MT; Novelli M; Bernengo MG
Dermatol Ther; 2010; 23(5):553-5. PubMed ID: 20868411
[TBL] [Abstract][Full Text] [Related]
11. A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib.
Giacchero D; Ramacciotti C; Arnault JP; Brassard M; Baudin E; Maksimovic L; Mateus C; Tomasic G; Wechsler J; Schlumberger M; Robert C
Arch Dermatol; 2012 Dec; 148(12):1418-20. PubMed ID: 23247489
[No Abstract] [Full Text] [Related]
12. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.
Hanrahan EO; Heymach JV
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4617-22. PubMed ID: 17671152
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Zhang X; Qin Y; Li H; Bai C; Zhu T; Xu J; Wu C; Wu M; Wang C; Song H; Wei L; He J
Asian Pac J Cancer Prev; 2011; 12(11):2857-63. PubMed ID: 22393954
[TBL] [Abstract][Full Text] [Related]
14. Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study.
Hsu C; Yang TS; Huo TI; Hsieh RK; Yu CW; Hwang WS; Hsieh TY; Huang WT; Chao Y; Meng R; Cheng AL
J Hepatol; 2012 May; 56(5):1097-1103. PubMed ID: 22245891
[TBL] [Abstract][Full Text] [Related]
15. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
Gustafson DL; Frederick B; Merz AL; Raben D
Cancer Chemother Pharmacol; 2008 Feb; 61(2):179-88. PubMed ID: 17393165
[TBL] [Abstract][Full Text] [Related]
16. A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid.
Zage PE; Zeng L; Palla S; Fang W; Nilsson MB; Heymach JV; Zweidler-McKay PA
Cancer; 2010 May; 116(10):2465-75. PubMed ID: 20225331
[TBL] [Abstract][Full Text] [Related]
17. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
Leboulleux S; Bastholt L; Krause T; de la Fouchardiere C; Tennvall J; Awada A; Gómez JM; Bonichon F; Leenhardt L; Soufflet C; Licour M; Schlumberger MJ
Lancet Oncol; 2012 Sep; 13(9):897-905. PubMed ID: 22898678
[TBL] [Abstract][Full Text] [Related]
18. Vandetanib for the treatment of medullary thyroid cancer.
Chau NG; Haddad RI
Clin Cancer Res; 2013 Feb; 19(3):524-9. PubMed ID: 23231950
[TBL] [Abstract][Full Text] [Related]
19. Vandetanib and the management of advanced medullary thyroid cancer.
Campbell MJ; Seib CD; Gosnell J
Curr Opin Oncol; 2013 Jan; 25(1):39-43. PubMed ID: 23202050
[TBL] [Abstract][Full Text] [Related]
20. Oral mucosal pigmentation induced by vandetanib therapy: First clinicopathological characterization.
Vigarios E; Maret D; Herbaut-Barres B; Zerdoud S; Sibaud V
Oral Oncol; 2020 Oct; 109():104747. PubMed ID: 32418862
[No Abstract] [Full Text] [Related]
[Next] [New Search]